- Home
- NBBK vs DNTH Comparison
NBBK vs DNTH Comparison
Compare NBBK & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- DNTH
- Stock Information
- Founded
- NBBK 1892
- DNTH 2015
- Country
- NBBK United States
- DNTH United States
- Employees
- NBBK 376
- DNTH N/A
- Industry
- NBBK
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- NBBK
- DNTH Health Care
- Exchange
- NBBK Nasdaq
- DNTH Nasdaq
- Market Cap
- NBBK 752.7M
- DNTH 780.2M
- IPO Year
- NBBK N/A
- DNTH N/A
- Fundamental
- Price
- NBBK $18.89
- DNTH $23.57
- Analyst Decision
- NBBK Buy
- DNTH Strong Buy
- Analyst Count
- NBBK 1
- DNTH 8
- Target Price
- NBBK $20.00
- DNTH $54.00
- AVG Volume (30 Days)
- NBBK 181.7K
- DNTH 381.4K
- Earning Date
- NBBK 10-29-2025
- DNTH 08-07-2025
- Dividend Yield
- NBBK 1.48%
- DNTH N/A
- EPS Growth
- NBBK 341.36
- DNTH N/A
- EPS
- NBBK 1.33
- DNTH N/A
- Revenue
- NBBK $179,117,000.00
- DNTH $4,854,000.00
- Revenue This Year
- NBBK N/A
- DNTH N/A
- Revenue Next Year
- NBBK N/A
- DNTH N/A
- P/E Ratio
- NBBK $14.22
- DNTH N/A
- Revenue Growth
- NBBK 28.24
- DNTH 17.87
- 52 Week Low
- NBBK $15.09
- DNTH $13.37
- 52 Week High
- NBBK $21.05
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- NBBK 61.06
- DNTH 58.94
- Support Level
- NBBK $18.81
- DNTH $23.24
- Resistance Level
- NBBK $18.88
- DNTH $25.41
- Average True Range (ATR)
- NBBK 0.46
- DNTH 1.54
- MACD
- NBBK 0.10
- DNTH 0.24
- Stochastic Oscillator
- NBBK 86.39
- DNTH 71.29
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.